Current Edition

Britain

Pfizer’s COVID pill Paxlovid gets boost in Britain thanks to spot in national trial

Pfizer’s COVID-19 vaccine and antiviral show little sign of slowing down in the pandemic’s third year. Now, the company’s oral therapy is getting a boost …

Continue Reading →
cancer

Novartis aims to keep canakinumab’s early lung cancer hopes alive despite metastatic failure

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said …

Continue Reading →
cancer

In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …

Continue Reading →
bladder

That key Gilead breast cancer readout? Try 2024, and don’t get your hopes up: analyst

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors …

Continue Reading →
breast

Gilead drops unclear win for key Trodelvy breast cancer trial, poking holes in CEO’s oncology plan

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …

Continue Reading →
cancer

Deciphera details stomach cancer flop against Pfizer’s Sutent, cracking the door open for off-label use

Deciphera Pharmaceuticals recently took a serious hit to its billion-dollar hopeful cancer drug Qinlock. As the company undertakes a round of layoffs to deal with the …

Continue Reading →
cancer

ASH: Senti Bio’s gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models

Engineered cell therapy has revolutionized the treatment of blood cancers, but precisely selecting the right target to kill off cancer cells while sparing healthy cells …

Continue Reading →
biotech

Totus tots up $40M in series A funding to go after competitive cancer space

Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to …

Continue Reading →
cancer

Considerations for Clinical Trial Design Involving Radiotherapy

Radiation therapy has been used for many years as an effective form of treatment against many cancer types, yet it remains less well researched and …

Continue Reading →
Bavencio

ESMO: Bristol Myers’ Opdivo-Yervoy, Pfizer-Merck KGaA’s Bavencio hit walls in head and neck cancer

Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck …

Continue Reading →